Based on the remarkable effect of PARP inhibitors in combination with AZD5363 or Ezetimibe in inhibiting TNBC cell lines, we finally tested the antitumor effect of different drug combinations in a 4T1 tumor-bearing mouse model. This evidence concerns the gene PARP1 and neoplasm.